INTS, BIO J INTS BIO Presents Interim Results from the Preclinical Study of 'JIN-001' in Refractory Ovarian Cancer: A Promising Solution for Overcoming Drug Resistance Published on 08/07/2025 at 18:04 | prnewswire.co.uk J INTS BIO South Korea Spain New York View original content:https://www.prnewswire.co.uk/news-releases/j-ints-bio-presents-interim-results-from-the-preclinical-study-of-jin-001-in-refractory-ovarian-cancer-a-promising-solution-for-overcoming-drug-resistance-302285396.html en | boerse | 67979901 |
